Patents by Inventor James E. Shields

James E. Shields has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4199501
    Abstract: Tetradecapeptides of the formula ##STR1## wherein X is H-Ala-D-Ala, H-D-Ala-Gly, or H-D-Val-Gly, and X.sup.1 is Phe or Cha, or a non-toxic pharmaceutically acceptable acid addition salt thereof, inhibit the secretion of growth hormone without materially inhibiting the secretion of glucagon or insulin. Intermediates and processes for making the tetradecapeptides are also described.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: April 22, 1980
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4199500
    Abstract: The tetradecapaptides of the formula ##STR1## wherein X is H-Ala-D-Ala, H-D-Ala-Gly, or H-D-Val-Gly, or the non-toxic, pharmaceutically acceptable acid addition salts thereof; inhibit the secretion of growth hormone, while not materially inhibiting the secretion of insulin or glucagon. Intermediates used in the synthesis of the tetradecapeptides are also described.
    Type: Grant
    Filed: November 20, 1978
    Date of Patent: April 22, 1980
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4100117
    Abstract: The tetradecapeptide ##STR1## is described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptide. This tetradecapeptide as well as its pharmaceutically-acceptable acid addition salts exhibit various activities including inhibition of the release of gastric acid and reduction of gut motility.
    Type: Grant
    Filed: April 21, 1977
    Date of Patent: July 11, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4093574
    Abstract: The tetradecapeptides ##STR1## in which Y is L-Asn or L-Ala are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. These tetradecapeptides as well as their pharmaceutically-acceptable acid addition salts exhibit various activities including inhibition of the release of gastric acid.
    Type: Grant
    Filed: February 2, 1977
    Date of Patent: June 6, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4087390
    Abstract: The tetradecapeptides ##STR1## in which Y is L-Asn or L-Ala are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. These tetradecapeptides as well as their pharmaceutically-acceptable acid addition salts exhibit various activities including inhibition of the release of gastric acid.
    Type: Grant
    Filed: February 2, 1977
    Date of Patent: May 2, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4076659
    Abstract: The tetradecapeptide ##STR1## is described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptide. This tetradecapeptide as well as its pharmaceutically acceptable acid addition salts inhibit the release of growth hormone and the release of gastric acid.
    Type: Grant
    Filed: March 17, 1976
    Date of Patent: February 28, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4062816
    Abstract: The tetradecapeptide ##STR1## is described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptide. This tetradecapeptide as well as its pharmaceutically acceptable acid addition salts inhibit the secretion of gastric acid.
    Type: Grant
    Filed: March 11, 1976
    Date of Patent: December 13, 1977
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4061626
    Abstract: The tetradecapeptides ##STR1## in which Y is Gly or D-Ala are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. The tetradecapeptide in which Y is Gly as well as its pharmaceutically acceptable acid addition salts exhibit as their principal activity the in vivo inhibition of the release of gastric acid. The tetradecapeptide in which Y is D-Ala as well as its pharmaceutically acceptable acid addition salts exhibit as their principal activity the in vivo stimulation of the release of growth hormone.
    Type: Grant
    Filed: April 29, 1976
    Date of Patent: December 6, 1977
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4061607
    Abstract: The tetradecapeptides ##STR1## in which Y is L-Cha, L-Leu, or D-Phe are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. These tetradecapeptides as well as their pharmaceutically-acceptable acid addition salts inhibit the release of growth hormone.
    Type: Grant
    Filed: July 28, 1976
    Date of Patent: December 6, 1977
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields